Literature DB >> 23352074

Analysis of the spectrum and antibiotic resistance of uropathogens in vitro: results based on a retrospective study from a tertiary hospital.

Kun Ling Ma1, Chang Xian Wang.   

Abstract

BACKGROUND: Antibiotic resistance of uropathogens in urinary tract infections (UTIs) is increasing worldwide. This study aimed to compare the spectrum and antimicrobial resistance of uropathogens in community-acquired UTIs (CAUTIs) and nosocomial-acquired UTIs (NAUTIs) at a tertiary hospital in China.
METHODS: Retrospective analysis of uropathogens from UTI patients was performed at Zhong Da Hospital.
RESULTS: A total of 1129 strains was isolated from 653 community-acquired and 476 nosocomial-acquired infections. Escherichia coli was the most common uropathogen, accounting for 55.9% of the CAUTIs and 27.1% of the NAUTIs. Among the CAUTIs, Escherichia coli was followed in prevalence by Enterococcus spp (12.9%) and Proteus mirabilis (3.7%). Among the NAUTIs, Escherichia coli was followed by Enterococcus spp (15.3%) and Klebsiella pneumoniae (6.9%). The proportion of fungi in the NAUTIs (23.7%) was higher than that in the CAUTIs (3.1%) (P < .05). Extended-spectrum β-lactamase-producing strains of E coli accounted for 70.6% of the NAUTIs and 47.3% of the CAUTIs. Carbapenems, amikacin, and nitrofurantoin were active agents against E coli. The resistance rates of E coli to cephalosporins, ampicillin, ampicillin/sulbactam, quinolones, and gentamicin were higher in the NAUTIs than in the CAUTIs (P < .05).
CONCLUSION: The distribution of species was different between CAUTIs and NAUTIs. Higher antibiotic resistance rates were observed in the NAUTIs than in the CAUTIs.
Copyright © 2013 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23352074     DOI: 10.1016/j.ajic.2012.09.015

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  7 in total

Review 1.  Proteus mirabilis and Urinary Tract Infections.

Authors:  Jessica N Schaffer; Melanie M Pearson
Journal:  Microbiol Spectr       Date:  2015-10

2.  Five-Year Antimicrobial Resistance Patterns of Urinary Escherichia coli at an Australian Tertiary Hospital: Time Series Analyses of Prevalence Data.

Authors:  Oyebola Fasugba; Brett G Mitchell; George Mnatzaganian; Anindita Das; Peter Collignon; Anne Gardner
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

Review 3.  Community-Acquired Urinary Tract Infection by Escherichia coli in the Era of Antibiotic Resistance.

Authors:  Dong Sup Lee; Seung-Ju Lee; Hyun-Sop Choe
Journal:  Biomed Res Int       Date:  2018-09-26       Impact factor: 3.411

4.  Genetic relatedness of the Enterococcus faecalis isolates in stool and urine samples of patients with community-acquired urinary tract infection.

Authors:  Zohreh Ghalavand; Masoud Alebouyeh; Kiandokht Ghanati; Leila Azimi; Marjan Rashidan
Journal:  Gut Pathog       Date:  2020-09-09       Impact factor: 4.181

5.  Molecular characterization of multidrug-resistant Klebsiella pneumoniae isolates.

Authors:  Xiang-hua Hou; Xiu-yu Song; Xiao-bo Ma; Shi-yang Zhang; Jia-qin Zhang
Journal:  Braz J Microbiol       Date:  2015-07-01       Impact factor: 2.476

Review 6.  Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies.

Authors:  Oyebola Fasugba; Anne Gardner; Brett G Mitchell; George Mnatzaganian
Journal:  BMC Infect Dis       Date:  2015-11-25       Impact factor: 3.090

7.  Temporal trends and risks factors for antimicrobial resistant Enterobacteriaceae urinary isolates from outpatients in Guadeloupe.

Authors:  Stéphanie Guyomard-Rabenirina; Joyce Malespine; Célia Ducat; Syndia Sadikalay; Mélanie Falord; Dorothée Harrois; Vincent Richard; Charles Dozois; Sébastien Breurec; Antoine Talarmin
Journal:  BMC Microbiol       Date:  2016-06-24       Impact factor: 3.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.